Chief Accounting Officer
Eledon Pharmaceuticals, Inc. (ELDN)Equibles does not estimate personal net worth.
Get an email with a short summary when Eledon Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ELDN alertsPaul Little is recorded as Chief Accounting Officer at Eledon Pharmaceuticals, Inc. (ELDN) since July 31, 2021 and CFO at Eledon Pharmaceuticals, Inc. (ELDN). The newest filing on record that lists Paul Little as CFO at Eledon Pharmaceuticals, Inc. (ELDN) is dated April 30, 2026. The proxy statement of Eledon Pharmaceuticals, Inc. reports total compensation of $1,592,943 for Paul Little in fiscal 2025, including a base salary of $479,226. Disclosed compensation is on record for 5 fiscal years. Paul Little has spoken on 9 earnings calls across 1 company, most recently for Eledon Pharmaceuticals, Inc. on May 11, 2023. Eledon Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Eledon Pharmaceuticals, Inc. includes David-Alexandre "DA" C. Gros, M.D. (CEO and Board Member), David-Alexandre C. Gros (CEO and Board Member), David-Alexandre C. Gros, M.D. (CEO and Board Member) and 7 others.
“Good afternoon, everyone, and thank you for joining Eledon's first quarter 2023 operating and financial results conference call. I am joined today on today's call by David-Alexandre Gros, Chief Executive Officer, and Steve Perrin, our President and Chief Scientific Officer.”
“Good afternoon, everyone, and thank you for joining Eledon's fourth quarter and full-year 2022 operating and financial results conference call.”
“Good afternoon, everyone, and thank you for joining Eledon’s third quarter 2022 operating and financial results conference call. Today, I’m joined by David-Alexandre Gros, Chief Executive Officer; Steve Perrin, our President and Chief Scientific Officer; and Jeff Bornstein, our Chief Medical Officer.”
“Good afternoon everyone and thank you for joining Eledon's second quarter 2022 operating and financial results conference call. I am joined on today’s call by David-Alexandre Gros, Chief Executive Officer; and Jeff Bornstein, Chief Medical Officer.”
“Good afternoon everyone and thank you for joining Eledon’s first quarter 2022 operating and financial results conference call. I am joined on today’s call by David-Alexandre Gros, Chief Executive Officer; Steve Perrin, President and Chief Scientific Officer; and Jeff Bornstein, Chief Medical Officer.”
2021-07-31–present
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
CFO, Chief Accounting Officer
2021-07-31–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Financial Officer | $479,226 | $1,592,943 |
| 2024 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Financial Officer | $459,431 | $3,090,335 |
| 2023 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Financial Officer | $441,448 | $1,321,176 |
| 2022 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Financial Officer | $421,051 | $1,057,392 |
| 2021 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Financial Officer | $323,269 | $2,307,958 |
